MaxCyte MXCT Business Segments — Other Nonoperating Income Expense

Similar metrics at other companies

DUOTTechnologies — Other Income

$1.48K-92.3%

AEIOther — Nonoperating Income Expense

-$2.54M+29.3%

BKRIndustrial & Energy Technology — Other Income (Expense)

$4M+300%

VAN

VANIBiopharm Division — Other Nonoperating Income Expense

-$209K+29.4%

LODECorporate And Other — Nonoperating Income Expense

-$458.27K-9.2%

MLTXOther Nonoperating Income

$3.21M-54.8%

Questions, answered.

What is MaxCyte's business segments — other nonoperating income expense?

MaxCyte (MXCT) reported business segments — other nonoperating income expense of $1.44M in Q1 2026.

How has MaxCyte's business segments — other nonoperating income expense changed year-over-year?

MaxCyte's business segments — other nonoperating income expense decreased by 29.4% year-over-year, from $2.03M to $1.44M.

What is the long-term trend for MaxCyte's business segments — other nonoperating income expense?

Over 2 years (2023 to 2025), MaxCyte's business segments — other nonoperating income expense has grown at a -16.3% compound annual growth rate (CAGR), from $10.38M to $7.27M.

What does business segments — other nonoperating income expense mean?

This metric captures financial impacts on the cell engineering technology segment that arise from activities outside of its primary commercial operations, such as interest income, interest expense, or foreign exchange gains and losses. It provides visibility into the segment's financial health beyond core product sales and licensing activities. Investors use this to understand how non-core financial items influence the segment's overall profitability.